GlycoMimetics (GLYC) Competitors

Adagene (NASDAQ:ADAG) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Does the MarketBeat Community prefer ADAG or GLYC?

GlycoMimetics received 294 more outperform votes than Adagene when rated by MarketBeat users. However, 79.31% of users gave Adagene an outperform vote while only 57.74% of users gave GlycoMimetics an outperform vote.

Company	Underperform	Outperform
Adagene	Outperform Votes 23 79.31%	Underperform Votes 6 20.69%
GlycoMimetics	Outperform Votes 317 57.74%	Underperform Votes 232 42.26%

Do analysts recommend ADAG or GLYC?

Adagene currently has a consensus target price of $8.00, indicating a potential upside of 421.17%. Given Adagene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Adagene is more favorable than GlycoMimetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
GlycoMimetics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Is ADAG or GLYC more profitable?

Adagene's return on equity of 0.00% beat GlycoMimetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
GlycoMimetics	N/A	-230.74%	-177.39%

Which has more risk & volatility, ADAG or GLYC?

Adagene has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500.

Does the media refer more to ADAG or GLYC?

In the previous week, GlycoMimetics had 1 more articles in the media than Adagene. MarketBeat recorded 5 mentions for GlycoMimetics and 4 mentions for Adagene. Adagene's average media sentiment score of 0.96 beat GlycoMimetics' score of 0.57 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlycoMimetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in ADAG or GLYC?

9.5% of Adagene shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 8.7% of GlycoMimetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, ADAG or GLYC?

Adagene has higher revenue and earnings than GlycoMimetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$103.20K	700.69	-$18.95M	N/A	N/A
GlycoMimetics	$10K	1,683.82	-$37.88M	-$0.59	-0.44

Summary

Adagene beats GlycoMimetics on 9 of the 14 factors compared between the two stocks.